The FDA has granted Amicus' AT-GAA a Breakthrough Therapy Designation (BTD) for the treatment of late onset Pompe disease.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.